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The standard of care for patients with multiple my-
eloma (MM) who are not eligible for high dose therapy + 
autologous stem cell transplantation (aged > 65 years or 
< 65 with severe comorbidities) has been for many years 
the combination of melphalan + prednisone (MP). In 
recent years, the novel drugs thalidomide, lenalidomide 
and bortezomib have been incorporated in the above-
mentioned ‘old’ regimen. It is becoming increasingly clear 
that addition of an individual novel agent to the traditional 
MP regimen could be synergistic and influence the disease 
outcome. Consequently, the appropriateness of the use 
and tolerability of such regimens in different patient popu-
lations is another area of active research interest. Five 
randomized studies comparing the MP plus thalidomide 
(MPT) regimen with MP alone have provided conflicting 
evidence [1-5]. Although there is greater agreement with 
regard to superior response rates (RRs) with MPT to MP, 
the impact on progression free survival (PFS) and overall 
survival (OS) is less clear, with some trials demonstrating 
an improvement in PFS and/or OS with MPT and others 
showing no difference in outcomes.
Importantly, the dose intensities of all three drugs (M, 
P, and T) differed among the five trials (Table 1). The op-
timal dose of thalidomide as an anti-myeloma therapy is 
not yet known, mainly because its exact mode of action is 
unclear. While traditional cytotoxic drugs show a dose-
response relationship within the therapeutic range, a simi-
lar correlation cannot necessarily be presumed to occur 
with immunomodulatory drugs. Thalidomide appears to 
be immunomodulatory as well as anti-angiogenic. Both 
these activities may contribute to the anti-myeloma effect 
of the drug, but the immunomodulatory action is thought 
probably to be the major contributor [6]. It has been sug-
gested that a threshold level of the active drug may need 
to be achieved to ‘switch on’ the immunomodulatory and, 
hence, the major anti-neoplastic mechanism, with further 
dose increases failing to enhance anti-neoplastic activity 
[7]. Moreover, pharmacokinetic data on thalidomide use in 
humans are not well-characterized and show considerable 
individual variation. The optimal dose probably needs to 
be individualized. 
Among the above five studies, melphalan and thalido-
mide doses were lowest in the IFM 01-01 study (involv-
ing patients above 75 years of age), yet it demonstrated a 
survival benefit [3]. The Nordic group demonstrated that 
better tolerated, lower thalidomide doses (100-200 mg) 
were sufficient and comparable to higher doses (400 mg) 
used in the induction phase, and 200 mg in the mainte-
nance phase [4]. Unfortunately, thalidomide has many 
side-effects, some of which are dose-related. Better RRs 
with such high doses did not translate into survival benefit 
in the MPT arm. Nearly a third of patients had discontin-
ued treatment by three months, and stopping of therapy 
increased to 56% by the end of the first year. Furthermore, 
during the first six months of treatment, the Nordic study 
reported 35 deaths in the MPT arm, 23 in patients older 
Correspondence to Chang-Ki Min, M.D. 
Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea School of Medicine, Banpo 4-dong, Seocho-gu, Seoul 137-
701, Korea
Tel: 82-2-2258-6053, Fax: 82-2-599-3589, E-mail: ckmin@catholic.ac.kr
See Article on Page 403-409Min CK. Low-thalidomide dose MpT    401
http://dx.doi.org/10.3904/kjim.2011.26.4.400 http://www.kjim.or.kr
than 75 years [4]. 
In this issue of the Korean Journal of Internal Medicine, 
Dr. Chang and colleagues [8] report that lower dose tha-
lidomide (50 mg per day) plus MP is effective in my MM, 
with 57.1% overall RRs and 23.8% complete RRs. Although 
MP doses with four-week cycles of melphalan (4 mg/m
2) 
and prednisone (40 mg/m
2) on days 1-7 are active in un-
treated MM, the daily doses used were low, and unlikely 
Table 1. Characteristics of 5 MPT trials
GIMEMA [1] IFM 99-06 [2] IFM 01-01 [3] NORDIC [4] HOVON 49 [5]
Accrual period
01/2002-05/2005 05/2000-08/2005 04/2002-12/2006 01/2002-05/2007 09/2002-07/2007
No. of patients 331 321 226 357 333
Median age, yr  72 69 78.5 74 72
Total no. of cycles planned    6 12 cycles q6 wk 12 cycles q6 wk Until plateau
8 cycles q4 wk, 





2 x 7 day 0.25 mg/kg x 4 day 0.2 mg/kg per day 
x 4 day
0.25 mg/kg x 4 day 0.25 mg/kg x 5 day
prednisone 40 mg/m
2 x 7 day 2 mg/kg x 4 day 2 mg/kg per day 
x 4 day
100 mg per day
x 4 day
1 mg/kg x 5 day
Thalidomide 100 mg per day Not standardized, 
400 mg per day 
maximum dose
100 mg per day 200 mg per day
x 7 day then 
400 mg per day
200 mg per day
Overall response rates, %
Mp  85 35  31 66 (including MR) 45
MpT   51 76 62 71 (including MR) 66
CR
Mp    4   2    1   4 NR
MpT  16 13   7 13 NR
CR + VGpR
Mp  15   7   7   7   8
MpT  45 47 21 23 28
pFS, mon
Mp 14.5 17.8 18.5 14  21
MpT 21.8 27.5 24.1 15 33
OS, mon
Mp 47.6 33.2 29 32  31
MpT  45 51.6 44 29 40
Grade 3-4 toxicity, %
peripheral neuropathy
Mp    0   0   2    1    4
MpT  10   6    2   6 23
Venous thromboembolism
Mp    2   4   3   8    0
MpT   11 12   6   8    3
Median duration of thalidomide   
 therapy, mon
9.6 11 13.5
7.7 for those living 
longer than 1 yr
8.4 as maintenance
MpT, melphalan + prednisone + thalidomide; Mp, melphalan + prednisone; MR, minimal response; CR, complete response; NR, no 
response; VGpR, very good partial response; pFS, progression free survival; OS, overall survival. 402    The Korean Journal of Internal Medicine Vol. 26, No. 4, December 2011
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to produce such high response rates. This is supported by 
others who reported ultra low doses of thalidomide 25 mg 
or 50 mg on alternate days, respectively [7,9]. One of the 
major implications of this study lies in the higher than ex-
pected RRs, despite the lower dose of thalidomide. There 
is not a clear dose-response relationship between tha-
lidomide and myeloma response using dose ranges of 50-
400 mg/day [10]. However, interpretation of these results 
should be approached with caution. An explanation for 
the high observed RRs with MP plus thalidomide 50 mg 
may be that the cohort represented a selected group who 
metabolized thalidomide slower than the average. The 
small number of patients enrolled in this study may have 
achieved adequate plasma levels of the active thalidomide 
metabolites, despite taking low doses. This study showed 
substantially similar RRs; however, it also showed a short-
er response duration than that seen in the IFM 01-01 trial 
[3]. The reason for the shorter PFS in this study may be 
that the patients were treated for a median four cycles of 
MPT (range, 1 to 12). 
A reduced dose of thalidomide with MP has the potential 
to decrease adverse effects and does not have to require 
dose reduction, as compared to conventional MPT. With 
respect to the withdrawal rate from the IFM 01-01 trial, 
48 patients (42.4%) discontinued treatment due to toxici-
ties, while two (10%) discontinued treatment in this study. 
However, grade 3-4 peripheral neuropathy was reported 
in one (5%) patient, which is comparable to other studies 
(Table 1). Moreover, the occurrence of venous thrombo-
embolism (VTE) was reported in 10% of patients in this 
study, but one unexplained death might be considered a 
composite adverse effect, suggesting that the percentage 
of VTE (approximately 15%) was substantially higher than 
in other studies (Table 1). The fact that the incidence of 
grade 3-4 adverse events was not significantly reduced in 
patients who received low-thalidomide dose MPT is incon-
sistent with the lower discontinuation rate in this study.
During the past 10 years, dramatic changes have oc-
curred in the treatment options for MM. The challenge 
now is to build on this progress and find new, more active, 
and less toxic agents and combinations. MP plus thalido-
mide 50 mg may be considered one of the new combina-
tion regimens for elderly and/or transplant ineligible MM 
patients. Randomized trials of varying thalidomide doses 
in patients receiving MPT would further advance the field 
and facilitate treatment tailored to the individual patient.
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